Johnson & Johnson secured an option to acquire Sail Biomedicines for up to $2.58 billion. This investment targets Sail’s novel in vivo chimeric antigen receptor (CAR-T) platform.
The deal includes $785 million in initial payments. J&J will provide a $465 million upfront equity investment as part of that total.
The collaboration aims to advance Sail’s lead program for immune-mediated diseases. The partners will also explore additional therapeutic targets.
Sail’s technology reprograms immune cells directly within the body. This in vivo approach eliminates the need to engineer patient cells in a laboratory.
The method aims to create scalable treatments for autoimmune conditions by resetting the immune system. This strategic move underscores pharmaceutical interest in therapies that are easier to administer than current methods.